Svar Life Science
We care about
the quality of your data
Back

CONTENTS

Go to the top of the page

Biomarker Discovery Services - leveraging our extensive immunoassay expertise!

At Svar Life Science, we are dedicated to providing innovative solutions and products that support the development of new therapeutics. Our CRO team -working on Biomarker Discovery Services- is committed to utilizing cutting-edge technologies and ensuring the accuracy and reliability of the results to meet your exploratory biomarker discovery needs.

With over 30 years of experience in developing, optimizing, and validating immunoassays, we leverage our expertise to apply the latest immunoassay technologies. This enables us to provide high-quality solutions to complex clinical questions early in discovery.

Biomarker Discovery in Drug Development

We provide protein biomarkers discovery services that have the potential of identifying novel drug targets in the early stages. The pharmaceutical industry relies heavily on these markers to uncover disease progression, responder signatures, diagnostic biomarkers, and potential new indications. The role of biomarkers in drug development is crucial as they provide valuable insights into the efficacy and safety of potential drug candidates.

Our exploratory biomarker discovery services are an effective tool that can help identify new biomarkers capable of monitoring disease progression, predicting treatment response, and assessing toxicity. Incorporating biomarkers discovery into your drug development can accelerate the process of developing life-saving therapies.

 

Ensuring the Accuracy and Reliability of Your Data Analysis with Our Expertise

 Olink Launch Hero (2100 × 1180 px)

To accelerate your biomarker discovery program, Svar Life Science offers the following services in a non-GxP setting:

  • Expert help with  assay setup 
  • Assay optimization
  • Sample analysis
  • Quality control of data
  • Data reporting

We offer two approaches to Biomarker Discovery: 

Artboard 1

1. High Quality Proteomics - Olink® PEA technology

Utilizing the unique Proximity Extension Assay (PEA) technology from Olink®, we offer ideal broad screening-to-targeted discovery solutions. 

Designed Panels with Relative Quantification (Target 96)

  • Simultaneous analysis of 92 protein biomarkers
  • Broad library of over 1100 established or exploratory protein biomarkers
  • Uses only 1 µL of biological sample
  • Relative quantification in NPX units

 

Olink Target 96

expand
Biological Process Panel (Target 96)

A broad selection of proteins associated with important biological functions, Cell Regulation, Development, Metabolism, and Organ Damage. See panel specifications on Olink's website

  • Olink Target 96 Organ Damage ( 92 )
    The assays in this panel include proteins involved in key biological processes such as response to stress, regulation of cell proliferation, cell cycle, and cell death/apoptosis.
  • Olink Target 96 Development ( 92 )
    The assays in this panel include proteins involved in key biological processes such as cell migration and motility, extracellular matrix organization, and neurogenesis.
  • Olink Target 96 Metabolism ( 92 )
    The assays in this panel include proteins involved in key biological processes such as cellular metabolic processes, cell surface receptor     signaling pathways, regulation of phosphorylation, and cell adhesion.
  • Olink Target 96 Cell Regulation ( 92 )
    The assays in this panel include proteins involved in key biological processes such as cell communication, apoptotic process, cell cycle, and cell differentiation.
  • Olink Target 96 Mouse Exploratory ( 92 )
    The assays in this panel include proteins involved in key biological processes such as cellular regulation, development, signal transduction, and stress responses
expand
Cardiovascular Panel (Target 96)

A broad selection of proteins associated with biological functions linked to cardiovascular diseases. See panel specifications on Olink's website

  • Olink Target 96 Cardiovascular II ( 92 )
    This panel contains known human cardiovascular and inflammatory markers as well as some exploratory human proteins with great potential as new CVD markers.
  • Olink Target 96 Cardiovascular III ( 92 )
    This panel contains known human cardiovascular and inflammatory markers as well as some exploratory human proteins with great potential as new CVD markers.
  • Olink Target 96 Cardiometabolic ( 92 )
    The assays in this panel include proteins involved in key biological processes such as cellular metabolic process, cell adhesion, immune response, and complement activation.
expand
Immuno-Oncology Panel (Target 96)

A broad selection of proteins associated with biological functions linked to immune response and immuno-oncology diseases. See panel specifications on Olink's website

  • Olink Target 96 Immuno-Oncology ( 92 )
    The biomarkers in this panel include proteins involved in processes such as the promotion and inhibition of tumor immunity, chemotaxis, vascular and tissue remodeling, apoptosis and cell killing, and metabolism and autophagy.
  • Olink Target 96 Immune Response ( 92 )
    The assays in this panel include proteins involved in key biological processes such as adaptive immune response, defense response to viruses, lymphocyte activation, inflammatory response, and cytokine-mediated signaling pathways.
expand
Inflammation Panel (Target 96)

A broad selection of proteins associated with inflammatory and immune response processes.  See panel specifications on Olink's website

Olink Target 96 Inflammation ( 92 )

  • This represents the most extensive panel available on the market for proteins associated with inflammatory diseases and related biological processes, enabling the investigation of protein signatures with high efficiency and robustness and accelerating the speed of finding new and relevant human protein biomarkers related to inflammation.
expand
Neurology Panel (Target 96)

A broad selection of proteins associated with neurological functions and associated diseases. See panel specifications on Olink's website

  • Olink Target 96 Neuro Exploratory ( 92 )
    The assays in this panel include a combination of exploratory and established markers with a focus on neurology-related diseases and biological processes such as axon development, neurogenesis, and synapse assembly. The established proteins include Neurofilament light polypeptide (    Uniprot no. P07196)*, which is an important marker for degenerative neurological diseases and traumatic brain injury.

  • Olink Target 96 Neurology ( 92 )
    The assays in this panel offer a mix of established markers related to neurobiological processes and neurological diseases (e.g. neural development, axon guidance, synaptic function, or specific conditions such as Alzheimer’s disease), as well as some more exploratory proteins with broader roles in processes such as cellular regulation, immunology, development, and metabolism. Of the 92 assays provided, 89 are unique to this panel.
expand
Oncology Panel (Target 96)

A broad selection of proteins associated with biological functions linked to the initiation and progression of cancer, such as angiogenesis, cell communication, cellular metabolic processes, apoptosis, cell proliferation/differentiation, etc. See panel specifications on Olink's website

  • Olink Target 96 Oncology II ( 92 )
    The panel comprises 92 putative cancer-related human proteins that participate in biological mechanisms that are central to the initiation and progression of cancer, e.g. angiogenesis, cell-cell signaling, cell-cycle control, and inflammation. 
  • Olink Target 96 Oncology III ( 92 )
    The panel comprises 92 human proteins that participate in biological mechanisms that are central to the initiation and progression of cancer, e.g. angiogenesis, cell communication, cellular metabolic processes, apoptosis, cell proliferation/differentiation, etc. This panel perfectly complements the Olink® Target 96 Oncology II panel, enabling the measurement of 184 proteins in 2 dedicated panels.

Designed Panels with Absolute and Relative Quantification (Target 48)

  • Allow for simultaneous analysis of 45 protein biomarkers
  • Uses only 1 µL of biological sample
  • Results reported in standard concentration units (pg/mL) or relative quantification (NPX units)

Olink Target 48

expand
Cytokine panel (Target 48)

A solution for cytokine studies and inflammation-related diseases, offering a broad selection of proteins associated with biological functions linked to inflammation - the most important proteins covering key pathways related to cytokine signaling and inflammatory processes are well covered. See panel specifications on Olink's website

  • Olink Target 48 Cytokine ( 45 )
    Olink’s Target 48 Cytokine panel is the high-performance solution for cytokine studies and inflammation-related diseases, with absolute or relative quantification. The thorough selection of biomarkers ensures that the most important proteins covering key pathways related to cytokine signaling and inflammatory processes are well covered.
expand
Cytokine Mouse (Target 48)
  • Olink Target 48 Cytokine Mouse (43)
    Olink Target 48 Mouse Cytokine Panel is the high-performance solution for in-depth view of cytokine signaling and inflammatory pathways for pre-clinical and translational research. It can be utilized across key application areas to deepen current understanding of molecular pathways involved in the disease initiation and progression. See panel specifications on Olink's website

 

Customized Biomarker Panels

Olink Flex

  • Allow for the combination of ~ 200  protein biomarkers 
  • Results reported in standard concentration units (pg/mL) or relative quantification (NPX units)
  • Simultaneous analysis of 21 protein biomarkers
    See panel specifications on Olink's website

Olink Focus

  • Broad library of over 5000 protein biomarkers
  • Customized panels for specific and exclusive studies
  • Results reported in standard concentration units (pg/mL) or relative quantification (NPX units)
  • Simultaneous analysis of 21 protein biomarkers
    See panel specifications on Olink's website

Read more about Olink Technology.

Contact Us to Discuss Your Project


2. Ultra-sensitive detection - Simoa™ technology

Utilizing high-quality single-molecule arrays (SimoaTM) technology, we can support your exploratory biomarker detection in a variety of biological matrices with a sensitivity in the femtomolar range, well below the detection limit of the best ELISAs.

Simoa assays are available in the following therapeutic areas: COVID-19, neurology, oncology, immunology, cardiology, and infectious diseases.

In addition, utilizing our 30 years of assay development experience, we can support you in developing high-quality Simoa-based assays for your specific needs.

Read more about Simoa Technology.

Biomarker Discovery: Key applications for success

Discovery Biomarker key applications

  • Enhanced drug target selection:
    Biomarkers can provide insights into the biological pathways involved in a disease, which can help researchers identify potential drug targets.
  • Establishment of better biofluid biomarkers:
    Biomarkers can be measured in a matrix of liquid biosamples, increasing accessibility and recurrence, and convenience of sampling.
  • Indication of drug mode of action:
    A deep understanding of disease biology provides insights into the mode of drug action.
  • Monitoring drug response:
    By analyzing biomarkers, researchers can monitor and potentially predict how patients will respond to different treatments, allowing for more personalized and effective therapies.

Maximize Your Sample Analysis with Our Expert Optimization

Our Biomarker Discovery Services provide exceptional support that helps maximize your sample analysis. Our team of experts is committed to providing you with expert optimization that meets your needs. We use cutting-edge technologies to make sure that you get accurate results that are reliable and reproducible.

 

“Biomarkers have proven to be valuable drug development tools that enhance target validation, thereby helping better understand mechanisms of action and enabling earlier identification of compounds with the highest potential for efficacy in humans.”   

– Front Matter. In Biomarkers in Drug Discovery and Development
(eds R. Rahbari, J. Niewaal and M.R. Bleavins)

 

Contact Our Biomarker Discovery Services Team

We would love to hear from you